RxDoctor Payments Data

Cyrus Mancherje, MD

Cardiovascular Disease · Fairfield, CANPI 1659398543

Payments from drug & device makers

$9,878in general payments, 2019–2025

Across 414 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$1K
  • Amgen$738
  • Merck$607
  • Johnson & Johnson$563
  • E.r. Squibb & Sons, L.L.C.$557
  • Novartis$547
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$9,62897%
  • Education$2503%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,878 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$458,522
Medicare patients
735
Services billed
4,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban180$208,854
EntrestoSacubitril/Valsartan141$167,697
XareltoRivaroxaban119$146,394
JardianceEmpagliflozin31$44,705
OzempicSemaglutide25$38,555
FarxigaDapagliflozin Propanediol12$9,843
Metoprolol Succinate311$4,911
Ranolazine ErRanolazine35$4,153
Rosuvastatin Calcium194$4,075
Bumetanide119$4,074
Clonidine19$3,495
Atorvastatin Calcium247$2,783
Nitroglycerin77$2,584
Carvedilol303$2,527
Diltiazem 24hr Er (Cd)Diltiazem Hcl42$1,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$267$208,854180 claims
NovartisEntresto$547$167,697141 claims
Johnson & JohnsonXarelto$563$146,394119 claims
Boehringer IngelheimJardiance$178$44,70531 claims
Novo NordiskOzempic$184$38,55525 claims
AstraZenecaFarxiga$323$9,84312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Fairfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →